BioSpace News Archive

Drug Development

Biopharma Update on the Novel Coronavirus: May 26

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 26, 2020.

May 26, 2020
·
4 min read
·
BioSpace Editorial Staff
Business

WHO Pauses Hydroxychloroquine Arm of COVID-19 Study Following Safety Concerns

Questions over the efficacy and safety of hydroxychloroquine continue to be raised following the World Health Organization’s decision to temporarily halt a study of the malaria drug as a potential treatment for COVID-19.

May 26, 2020
·
3 min read
·
Alex Keown
Biotech Bay

Insitro Eyes Technology Expansion with $143M Series B Funding Round

The funding will be used to continue to build the company’s technology and automation, which enable data generation at a larger scale. This will expand Insitro’s ability to create predictive models of human disease.

May 26, 2020
·
3 min read
·
Krystle Vermes
Pharm Country

With New Strategic Focus, Sanofi Sells Off Regeneron Investments to Finance the Future

Sanofi is selling off its nearly $13 billion in investments in longtime development partner Regeneron as the France-based company shifts its strategy to focus on indications such as oncology, neurology, rare diseases and hematology.

May 26, 2020
·
3 min read
·
Alex Keown
Business

Merck Takes 3 Major Shots at COVID-19: Themis, IAVI and Ridgeback Bio

Merck has largely stayed out of the COVID-19 battle, but exploded into it with three major deals and collaborations today.

May 26, 2020
·
4 min read
·
Mark Terry
Drug Development

Argenx’s Myasthenia Gravis Drug, Efgartigimod, Shows Positive Results in Late-Stage Trial

Argenx, based in Breda, the Netherlands, and Ghent, Belgium, announced positive topline results from its Phase III ADAPT clinical trial of efgartigimod for Myasthenia Gravis (MG).

May 26, 2020
·
3 min read
·
Mark Terry
Policy

FDA Grants Priority Review to Alnylam’s RNAi Therapy Lumasiran for Primary Hyperoxaluria Type 1

Alnylam Pharmaceuticals’ lumasiran for a chronic kidney stone disease was granted Priority Review status by the U.S. Food and Drug Administration. It will have a target action date of December 3, 2020.

May 26, 2020
·
3 min read
·
Mark Terry
Drug Development

CEPI-Backed Novavax Doses First Patients with COVID-19 Vaccine Candidate

The Maryland-based company has enrolled and dosed its first patients in a Phase I/II study.

May 26, 2020
·
3 min read
·
Alex Keown
FDA

Sanofi and Regeneron’s Dupixent Scores Another Approval for Dermatitis, This Time in Kids

To date, Dupixent is the only biologic approved for this age group.

May 26, 2020
·
3 min read
·
Mark Terry
Business

Nordic Nanovector ASA: Results for the First Quarter 2020

Nordic Nanovector ASA announces its results for the first quarter 2020. A presentation by Nordic Nanovector’s senior management team will take place via a webcast at 08:30 am CET.

May 26, 2020
·
6 min read